Spatial Sequencing Services

G4X TECHNOLOGY ACCESS

Access tomorrow’s in-situ sequencing technology today with cost-effective spatial multiomic services. Analyze targeted spatial transcriptomics, proteomics, and fH&E on each FFPE sample with single-cell resolution.

Get in contact

It's time to scale your spatial multiomics

1 Flow Cell

Transcripts

Proteins

fH&E

Transcripts, Proteins, and fH&E

Image shows Transcript, Protein, fH&E readout of serial kidney tumor FFPE sections (10x10mm) from 1 of 4 flow cells in a G4X run

Get Started With Your Project Today

Standard Projects

Unlock insights with our immuno-oncology (IO) transcriptomic and proteomic panels across select supported Human FFPE tissues.

Modalities Tissue Types Customization
Standard
  • IO Transcript (300)
  • IO Protein (12)
  • fH&E
  • Tonsil
  • Kidney
  • Colon
  • Lymph
  • Breast
  • Lung
 None

Custom Projects

Choose from several customization options from add-on targets to fully custom panels to support your specific project needs.

Modalities Tissue Types Customization
Standard Plus
  • IO Transcript (300 + 25)
  • IO Protein (12)
  • fH&E
  • Tonsil
  • Kidney
  • Colon
  • Lymph
  • Breast
  • Lung
  • RNA Only: < 25 add-on
  • RNA Targets
Advanced
  • IO or New Transcript (300)
  • IO Protein (12 + 2)
  • fH&E
  • Any Human FFPE
  • RNA: Full Custom up to 300 targets
  • Protein: Add on 2 targets to Standard IO Panel
Pro
  • IO or New Transcript (300)
  • IO Protein (15)
  • fH&E
  • Any Human FFPE
  • Mouse FFPE
  • RNA: Full Custom up to 300 targets
  • Protein: Full Custom up to 15 targets

Connect with a Spatial Expert

Discuss your project and experimental design with a member of the Singular team to get started.

GET IN CONTACT
VIEW GENE LIST

Technology Access Services Information

Please provide your information and a member of the team will be in contact to provide more information on the Technology Access Services.

Download the Gene List

Please provide your information to download the gene list.

Drew Spaventa

Drew founded Singular Genomics in 2016 serving as the CEO and Chairman. Drew is a serial entrepreneur and venture investor in the biotech industry and has been involved in the founding of several successful companies. Prior to Singular Genomics, Drew founded Truvian Sciences, a low volume blood testing technology aimed at making routine blood tests easier, less invasive, and more affordable. Drew was also involved in the founding of Aspen Neurosciences where he co-led the seed financing and helped assemble a world-class team to combat Parkinson’s Disease using a patient’s own stem cells. Drew was also a seed investor and held an operating role in Edico Genome which sold to Illumina in 2018.

Drew received an MBA from the Rady School of Management at the University of California, San Diego and a BA in Political Science and International Relations from the University of California, San Diego.

Drew Spaventa

Max Reads Application Note